𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers

✍ Scribed by Dihua Yu

Book ID
114105432
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
804 KB
Volume
28
Category
Article
ISSN
0093-7754

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Downregulation of erbB3 abrogates erbB2-
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells
✍ Bolin Liu; Dalia Ordonez-Ercan; Zeying Fan; Susan M. Edgerton; XiaoHe Yang; Ann πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 654 KB

## Abstract Receptor tyrosine kinase activity is essential for erbB2 (HER2/__neu__) promotion of breast carcinogenesis, metastasis and therapeutic resistance. erbB2 kinase can be activated by dimerization with another erbB receptor, most of which bind ligands. Of these, the erbB2/erbB3 heterodimer

Combined trastuzumab and paclitaxel trea
Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone
✍ Kristine S. Klos; Xiaoyan Zhou; Sangkyou Lee; Lianglin Zhang; Wentao Yang; Yoich πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 209 KB

## Abstract ## BACKGROUND Trastuzumab (Herceptin; Genentech, South San Francisco, CA) is a humanized anti‐ErbB‐2 monoclonal antibody that has demonstrated antitumor function, especially in combination with other chemotherapies such as paclitaxel (Taxol; Bristol Myers‐Squibb, Princeton, NJ), in pat